Passage Bio, Inc., a clinical-stage genetic medicines company, has announced a 1-for-20 reverse stock split of its outstanding common shares, effective July 14, 2025. This move, approved by the company's Board of Directors, will reduce the number of shares from approximately 62.4 million to about 3.1 million. The reverse stock split is aimed at meeting Nasdaq's minimum bid price requirement of $1.00 per share. Passage Bio's common stock will continue trading under the symbol "PASG" with a new CUSIP number.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.